drugset / Trial / NCT00003665

Vaccine Therapy in Treating Patients With Stage IV Melanoma

NCT00003665

Phase 1 Completed 40 enrolled National Cancer Institute (NCI)
RandomizedParallel-groupOpen-labelTreatment

Summary

Randomized phase I trial to study the effectiveness of vaccine therapy in treating patients who have stage IV melanoma. Vaccines may make the body build an immune response to kill tumor cells.

Timeline

Start
1999-04
Primary completion
2002-10
Completion
2002-11

Drugs

EvaluationDrugModalityDoseRoute
Subject dendritic cell-MART-1 peptide vaccine Vaccine Intravenous
Background Tumor Infiltrating Lymphocytes Cell therapy
Background gp100 antigen Peptide
Background tyrosinase peptide Peptide

Indications